People: AEterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

0.55USD
1 Apr 2015
Change (% chg)

$0.01 (+2.00%)
Prev Close
$0.54
Open
$0.55
Day's High
$0.55
Day's Low
$0.53
Volume
226,302
Avg. Vol
1,603,911
52-wk High
$1.54
52-wk Low
$0.48

Search Stocks

Sachse, Richard 

Dr. Richard Sachse, M.D., Ph.D. is the Senior Vice President, Chief Scientific Officer, Chief Medical Officer of Aeterna Zentaris Inc. Dr. Sachse holds a degree in medicine from the Friedrich-Alexander-University Erlangen, in Germany, and a board certification in Clinical Pharmacology. With more than 20 years experience as a physician and scientist, he has extensive expertise in a variety of different therapeutic areas, including endocrinology and oncology. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic, as well as in the design and implementation of clinical pharmacology programs, including all required profiling studies and activities, enabling successful registration of products at the international level. From 1996 to 2000, he was International Project Leader at the Bayer AG Institute for Clinical Pharmacology, and Principal Investigator at the Bayer Clinical Pharmacology Unit, implementing innovative exploratory development tools, including biomarkers to demonstrate early Proof of Concept. From 2001 to 2006, Dr. Sachse held a variety of different management positions within early and late phase clinical development programs, including responsibilities for completed Phase 3 programs leading to successful NDA/MAA submissions. In 2007, after a merger, he became Senior Director, Head of Experimental Medicine, at UCB in Belgium, where he managed the implementation of novel biomarkers in clinical development to provide data supporting identification of appropriate target indication and target population. In 2010, Dr. Sachse became Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Dodd

1,279,000

Dennis Turpin

403,092

Philip Theodore

--

Richard Sachse

--

Jude Dinges

259,884

Keith Santorelli

--
As Of  30 Dec 2013
Search Stocks